Research Article
A Multicentre Randomized Clinical Trial on Efficacy and Safety of Huxin Formula in Patients Undergoing Percutaneous Coronary Intervention
Table 3
Major end points at 360 days.
| | Events | | Control group
() | Treatment group
() | | value |
| | Death | Y | 2 (0.7) | 0 (0.0) | 2.00 | 0.16 | | N | 293 (99.3) | 294 (100.0) |
| | Nonfatal MI | Y | 0 (0.0) | 0 (0.0) | — | — | | N | 295 (100.0) | 294 (100.0) |
| | Repeat revascularization | Y | 2 (0.7) | 3 (1.0) | 0.21 | 0.65 | | N | 293 (99.3) | 291 (99.0) |
| | Readmission | Y | 5 (1.7) | 9 (3.1) | 1.19 | 0.28 | | N | 290 (98.3) | 285 (96.9) |
|
|
Values are (%). MI: myocardial infarction.
|
